News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Henlius (02696.HK) HLX07 Combined with HANSIZHUANG Clinical Trial Approved to Commence in Australia
Henlius (02696.HK) announced that a Phase 2/3 clinical trial of its self-developed pimurutamab HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) in combination ...
Reset
Send
The window will close in 5 seconds
Henlius (02696.HK) HLX07 Combined with HANSIZHUANG Clinical Trial Approved to Commence in Australia
Close
Recommend
0
Positive
1
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

Henlius (02696.HK)  +3.500 (+4.416%)    Short selling $16.55M; Ratio 16.136%   announced that a Phase 2/3 clinical trial of its self-developed pimurutamab HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) in combination with HANSIZHUANG (serplulimab injection) and chemotherapy, compared with placebo plus HANSIZHUANG or pembrolizumab and chemotherapy, as first-line treatment for advanced squamous non-small cell lung cancer, has been approved by the relevant Human Research Ethics Committee and has completed clinical trial notification filing with the Therapeutic Goods Administration of Australia. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-24 16:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.